Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression

Ronald S. Duman, PhD

A role for damage and protection of neurons in the pathophysiology and treatment of psychiatric illness, including major depressive disorder (MDD) is based on molecular, cellular, and morphological studies in experimental animals and in human patients. Preclinical studies demonstrate that chronic stress causes alterations to the number and shape of neurons and glia in brain regions implicated in mood disorders. Advances in human brain imaging have also reported decreased volumes of limbic brain regions implicated in depression. Preclinical and postmortem studies of signal transduction pathways and target genes have extended this work at the molecular level, demonstrating dysregulation of neurotrophic factors and neuroprotective mechanisms in response to stress and in depressed patients. Conversely, chronic administration of therapeutic agents blocks the effects of stress or leads to induction of neurotrophic and neuroprotective pathways. Together, these findings have contributed to a fundamental shift in our understanding of the cause and treatment of psychiatric illnesses and the role of neurotrophic and neuroprotective mechanisms.

This review will present evidence demonstrating neuronal damage, atrophy, and cell loss in response to stress and depression, and the mechanisms underlying these effects. Studies demonstrating the neuroprotective actions of therapeutic agents that counteract the effects of stress and depression will also be discussed. Related aspects of this work are the effects of environment, cellular stressors, insults, and interactions with genetic factors that increase susceptibility and thereby cause dam-

The discovery that stress and depression, as well as other psychiatric illnesses, are characterized by structural alterations, and that these changes result from atrophy and loss of neurons and glia in specific limbic regions and circuits, has contributed to a fundamental change in our understanding of these illnesses. These structural changes are accompanied by dysregulation of neuroprotective and neurotrophic signaling mechanisms that are required for the maturation, growth, and survival of neurons and glia. Conversely, behavioral and therapeutic interventions can reverse these structural alterations by stimulating neuroprotective and neurotrophic pathways and by blocking the damaging, excitotoxic, and inflammatory effects of stress. Lifetime exposure to cellular and environmental stressors and interactions with genetic factors contribute to individual susceptibility or resilience. This exciting area of research holds promise and potential for further elucidating the pathophysiology of psychiatric illness and for development of novel therapeutic interventions.
State of the art

Selected abbreviations and acronyms

| Abbreviation | Definition |
|--------------|------------|
| ADT          | antidepressant treatment |
| AMPA         | α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid |
| BDNF         | brain derived neurotrophic factor |
| IDO          | indoleamine 2,3-dioxygenase |
| MDD          | major depressive disorder |
| NMDA         | N-methyl-D-aspartic acid |
| PFC          | prefrontal cortex |
| TNF          | tumor necrosis factor |

age and illness (Figure 1). Conversely, life history of behavior or therapies that reduce stress and enhance neuronal survival, such as exercise, diet, medications, and interactions with genetic factors that increase resilience are neuroprotective, and reverse or block the damaging effects of stress.

In addition, cellular growth and survival are intimately controlled by neuronal activity (Figure 1). This is due to the activity-dependent requirement for expression of neurotrophic factors and other survival pathways and mechanisms that control neurotransmission and neuroplasticity, as well as proliferation, growth, and survival.

Structural/cellular alterations in mood disorders

Depression, like most other major psychiatric illnesses, is widely accepted to be caused by neurochemical imbalances in regions of the brain that are known to control mood, anxiety, cognition, and fear. These regions include the hippocampus, prefrontal cortex (PFC), cingulate cortex, nucleus accumbens, and amygdala. In addition, brain imaging and postmortem studies have identified structural alterations in MDD patients that indicate reductions in dendrite arborization and complexity, and decreased numbers of neurons and glia in these brain regions, all of which could contribute to depressive symptoms (Figure 2). Together, these findings provide compelling evidence for disruption of neurotrophic factors and neuroprotective mechanisms in the pathophysiology of depression.

Structural alterations

One of the regions of interest in depression, as well as other disorders, is the hippocampus, a structure that contains high levels of receptors for glucocorticoids. Imaging studies have consistently reported that the volume of the hippocampus is decreased 10% to 20% in MDD patients.9,10,11,12 There is also evidence of a negative correlation with the length of illness and reversal with antidepressant treatment (ADT).13 but additional studies are needed to further examine these relationships and to determine whether the reduction is a result or a cause of depressive illness. It is also notable that hippocampal volume reductions have been reported in other stress-related illnesses, including post-traumatic stress disorder (PTSD)14,15 and schizophrenic patients16.

The PFC is another “stress-responsive” brain region implicated in depression. The primary function of the PFC is cognition, working memory, and inhibitory control of brain regions that underlie fear and emotion. Brain imaging studies have reported a significant reduction in the volume of the PFC in MDD patients, which could underlie the reported hypofunction of this structure, most notably decreased cognition.15,17,18

Cellular alterations

Different types of cellular alterations could account for the volume reductions observed in the hippocampus,
including reductions in the number, size, and proliferation of neurons and glia. There is one report that the size of neurons in the major subfields of the hippocampus is reduced, suggesting a reduction in neuropil that could contribute to decreased hippocampal volume in MDD patients. There were no changes in the numbers of neurons or glia reported in this study or in other qualitative studies, although more subtle synaptic changes have been reported.

Studies of the PFC and cingulate cortex have been more extensive, and have shown a reduction in the size of neuronal cell bodies, suggestive of reduced dendritic arborization and complexity. In addition, the most consistent finding in studies of PFC is a decrease in the number of glia in MDD patients. Reductions of both astrocytes and oligodendrocytes have been reported. Given the significant role of glia in providing metabolic support for neurons as well as control of neurotransmitter activity (eg, synthesis and reuptake), it is reasonable to speculate that neuronal atrophy, damage, and hypofunction of PFC could be related to the loss of glia.

**Cellular alterations in animal models of depression**

Animal models of depression have been used to further elucidate the ultrastructural and molecular alterations that underlie the morphological changes observed in MDD patients. Most of these models are based on acute or chronic-stress paradigms, as stress is a critical factor in the etiology of depression. In addition, these models have been used to demonstrate that antidepressants can reverse or block the effects of stress on cellular morphology, which might contribute to the therapeutic actions of these agents.

**Cell morphology**

Early studies of cell morphology found that repeated stress causes atrophy of CA3 pyramidal neurons in the hippocampus, characterized by a decreased number and length of apical dendrites. More recent studies have shown that pyramidal neurons in the PFC undergo a similar retraction/atrophy of apical dendrites, and a reduction in spine number in response to immobilization stress (Figure 2). Chronic exposure to high levels of exogenous corticosterone, the rodent equivalent of cortisol, causes a similar atrophy of hippocampal and PFC neurons.

In contrast to most neurological disorders, in which the structural alterations and loss of neurons is permanent, the stress-induced atrophy of hippocampal and PFC neurons is reversible. Most notably, removing animals from stress normalizes the dendritic arborization of pyramidal neurons over a period of several weeks. Moreover, chronic administration of certain antidepressants blocks or reverses hippocampal atrophy, even with continued stress exposure. This reversibility supports...
the notion that dendritic alterations represent a type of structural plasticity that has functional consequences.

**Cell proliferation**

In addition to dendritic atrophy, chronic stress decreases the proliferation of new cells in the adult hippocampus and PFC. The dentate gyrus of the hippocampus is one of the few regions of the brain that continues to give rise to new neurons in adulthood, in rodents as well as non-human primates and humans.35,36 Interestingly, the rate of neurogenesis is influenced by environmental and endocrine factors, and stress is one of the most consistent and robust negative regulators (Figure 2). The proliferation of new neurons is decreased by different types of stress, including restraint, footshock, maternal separation, predator odor, psychosocial stress, and sleep deprivation, and by administration of exogenous corticosterone.37 In the PFC the proliferation of glia is decreased by exposure to repeated stress38 or corticosterone treatment.39 Chronic stress also decreases the number of glial fibrillary acidic protein (GFAP)-positive astrocytes in the hippocampus.40 In contrast, antidepressants increase the proliferation of neurons and glia in the hippocampus and/or PFC, and block or reverse the effects of stress.41,42,43 These effects require chronic administration (weeks), consistent with the time course for the therapeutic response to antidepressants. Different classes of antidepressant increase cell proliferation in rats, including serotonin selective transporter inhibitors, norepinephrine selective reuptake inhibitors (NSRIs), and electroconvulsive seizures (ECS),41,43,44 indicating that this is a common target of ADT.

**Behavioral consequences of altered cell morphology**

A major question is whether the cellular alterations lead to changes in behavior. This has been addressed by blockade studies (ie, focused irradiation or genetic manipulation), which demonstrate that neurogenesis is required for the actions of antidepressants in certain behavioral models.42,43,46 although there are exceptions.47,48 Ablation of glia in the PFC decreases sucrose consumption, a measure of anhedonia, indicating a requirement for glial function in this model.40 Decreased PFC dendrite arborization in response to stress is also correlated with a reduction in attention set shifting, a PFC-dependent behavior.30 These studies demonstrate a causal and/or correlative relationship between cell number and complexity with behavior.

**Importance of life stress/trauma: gene-environment interactions**

There is also evidence that exposure to traumatic or stressful life events can have a cumulative effect that increases susceptibility or vulnerability to mood disorders51 (see Figure 1). Interactions of stress and genetic factors have also been reported, most notably for lifetime stress and the serotonin (5-HT) transporter short allele polymorphism;42 however, a recent meta-analysis suggests that additional studies of this polymorphism are required.43 Studies of genes that increase resilience to stress and mood disorders have also been conducted.54 Recent studies have also reported an interaction between early life stress or trauma and neurotrophic factors (see below).

**Mechanisms underlying structural alterations and neuroprotection: gene-environment interactions**

Cellular and structural alterations in response to stress, depression, and antidepressant medications could result from a number of different mechanisms that alter the proliferation, growth, survival, and function of neurons and glia. These include altered neurotrophic/growth factor support, excitotoxicity, inflammation/cytokines, metabolic/vascular support, viral, and toxic insults. The influence of these factors and insults on cell function and survival could occur rapidly after a single major event or could occur gradually over time with the accumulation of one or more insults, also referred to as allostatic load (Figure 1).55 The effects of these cellular stressors and insults are also influenced by genetic factors that can either increase susceptibility to cellular damage, or conversely decrease susceptibility and increase resilience and neuroprotection. This complex interaction of gene-environment interactions over the lifespan is thought to contribute to the heterogeneity of depression, other psychiatric illnesses, as well as treatment of these disorders. Characterization of the molecular mechanisms and genetic factors that underlie the structural alterations and that play a key role in neuroprotection will provide
important information for the diagnosis and treatment of depression. The following sections will discuss the major molecular and cellular mechanisms underlying the actions of stress, depression, and ADT. The latter will include not only chemical antidepressants, but also other strategies that have neuroprotective actions, including exercise. As discussed above, postmortem studies demonstrate a decrease in the size, but not the number, of neurons, indicating that cell death probably does not play a major role in depression. These findings suggest that mechanisms that control maintenance of neuronal size and function, and counteract stress-induced atrophy, such as neurotrophic factors, could be critical mediators. Other important mechanisms to be discussed are glutamate excitotoxicity, apoptosis, and inflammation/immune responses.

Neurotrophic/growth factors

The nerve growth factor (NGF) family has been the focus of much of the work on stress and depression, and the most widely studied member of this family is brain derived neurotrophic factor (BDNF). In addition, several other growth factors, including VEGF, IGF-1, and FGF2 have also been implicated in the effects of stress, depression, and ADT. Because these factors play a critical role in the proliferation, growth, and survival of neurons and glia in the adult brain, their altered expression or function could contribute to the cellular and morphological changes in animal models of depression and in MDD patients. This section will review key evidence demonstrating dysregulation of neurotrophic/growth factors in stress and depression.

Role of BDNF in stress, depression, and ADT

BDNF and related family members, including NGF and neurotrophin-3 (NT-3), influence the proliferation, differentiation, and growth of neurons during development, but are also expressed in the adult brain and play a critical role in the survival and function of mature neurons. BDNF is expressed at relatively high levels in limbic brain structures implicated in mood disorders, including the hippocampus, PFC, and amygdala, and acts through a transmembrane tyrosine kinase receptor referred to as TrkB. Functional BDNF acts as a dimer to stimulate the intracellular tyrosine kinase domain of TrkB, resulting in autophosphorylation of the receptor and interactions with docking proteins that lead to activation of one of three major intracellular signaling cascades: the microtubule associated protein kinase (MAPK), the phosphatidylinositol-3 kinase (PI3K), and the phospholipase-C-γ (PLCγ) pathways (Figure 3). These cascades have been linked to the neuroprotective effects of BDNF, as well as regulation of cell proliferation, differentiation, and survival.

Stress, depression, and regulation of BDNF

Smith and colleagues were the first to report that exposure to immobilization stress results in a dramatic reduction in levels of BDNF in the rodent hippocampus, and this effect has been reported with many other types of stress. Decreased expression of BDNF is observed in the major subfields of the hippocampus, including those layers where dendritic atrophy (CA3 pyramidal cell layer) and decreased neurogenesis (dentate gyrus granule cell layer) are observed in response to stress. Expression of BDNF in the PFC is also decreased by chronic, but not acute stress. Postmortem studies are consistent with the rodent work, reporting decreased levels of BDNF in the hippocampus of suicide-MDD subjects. These findings provide further support for the hypothesis that the morphological and behavioral abnormalities associated with MDD could result, in part, from decreased BDNF expression. There are several possible mechanisms that could underlie the regulation of BDNF by stress. This includes a reduction of neuronal firing, as BDNF expression is dependent on activity and Ca^{2+}-stimulated gene transcription. BDNF expression is also decreased by adrenal-glucocorticoids, which are induced by stress and activation of the hypothalamo-pituitary-adrenal (HPA) axis. There is also evidence that downregulation of BDNF by acute stress is mediated by interleukin-1β (IL-1β), and epigenetic regulation of BDNF expression in response to chronic social defeat stress.

Genetic studies of BDNF and interactions with stress

A relationship between BDNF, morphology, and behavior is supported by genetic studies of BDNF. Most of this work has focused on a functional polymorphism, Val66Met, that decreases the processing and release of BDNF. The Met allele has been associated with reduced hippocampal size and decreased memory and executive function in humans. The met allele has also been asso-
Figure 3. Regulation of neurotrophic/growth factors signaling is decreased by stress and increased by antidepressant treatment. Activation of these pathways leads to neuroprotection, survival, resilience, antiapoptosis, and proliferation of neurons and glia in limbic brain regions. 5-HT, 5-hydroxytryptamine; NE, norepinephrine; GPCR, G protein coupled receptor; AC, adenylyl cyclase; Gs, stimulatory G protein; cAMP, cyclic adenosine 3’,5’-monophosphate; PKA, cyclic AMP-dependent protein kinase; CREB, cyclic AMP response element binding protein; VEGF, vascular endothelial growth factor; IGF-1, insulin-like growth factor-1; FGF2, fibroblast growth factor-2; BDNF, brain derived neurotrophic factor; IRS, insulin receptor substrate; FRS, fibroblast growth factor receptor substrate; Grb2, adaptor protein; Sos, guanine nucleotide exchange factor; PI-3K, phosphatidylinositol 3’-kinase; Akt, protein kinase B, serine/threonine kinase; GSK-3, glycogen synthase kinase-3; Bad, proapoptotic factor; Ras, small guanosine triphosphatase; Raf, serine/threonine kinase; MEK, ERK kinase; ERK, extracellular signal regulated kinase; Rsk, ribosomal S6 kinase; Shc, Src homology domain adaptor protein; IL-1β, interleukin-1β; IKK, kappaB inhibitory protein kinase; IkB, kappaB inhibitory protein; NFκB, nuclear factor kappaB; Bcl2, antiapoptotic factor.
BDNF has also been implicated in depression, suggesting that increased expression of BDNF is a common target for different therapeutic strategies. Postmortem studies also demonstrate that BDNF levels are increased in the hippocampus of patients receiving antidepressant medication at the time of death, demonstrating the clinical relevance of ADT induction of BDNF. These effects are thought to occur via activation of cAMP and/or Ca²⁺-dependent BDNF gene transcription that are activated by ADT.

**Neuroprotective, neurogenic, and behavioral actions of BDNF**

The neuroprotective effects of BDNF have been well documented, primarily in cultured cell systems, but also in vivo. This includes studies demonstrating that BDNF increases survival and has neuroprotective actions in models of hypoxia, ischemia, excitotoxicity, hypoglycemia, and inflammation; for reviews see refs 92,93. As discussed above, hippocampal pyramidal cell dendrite complexity is decreased in BDNF Met allele or heterozygous deletion mutants. Similar effects have been observed in PFC pyramidal cells, and stress does not produce further atrophy of apical dendrites in BDNF heterozygous deletion mutants, indicating that decreased BDNF underlies the effects of stress. These findings indicate that a full complement of functional BDNF is required for maintenance of normal dendritic arbor in both the hippocampus and PFC.

BDNF has also been shown to influence hippocampal neurogenesis. Infusions of BDNF increase hippocampal neurogenesis, and BDNF is necessary for the survival of new neurons in response to ADT. The BDNF receptor, TrkB, is also required for antidepressant induction of hippocampal neurogenesis, as well as the behavioral actions of antidepressants. BDNF has also been implicated in the behavioral actions of ADT. BDNF infusions are sufficient to produce an antidepressant response in rodent behavioral models of depression, and mutant mouse studies demonstrate that BDNF is required for the behavioral actions of antidepressants. These findings are consistent with the hypothesis that induction of BDNF contributes to the neurogenic and behavioral actions of antidepressants.

**Other neurotrophic/growth factors**

There is now strong evidence demonstrating a role for several other growth factors in the actions of stress,
depression, and ADT, including vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), and insulin-like growth factor 1 (IGF-1). VEGF was originally characterized as a vascular permeability factor and an endothelial cell mitogen, but is also expressed in the brain in both neurons and glia, and has been shown to play a role in hippocampal neuroplasticity, memory, and neurogenesis. Chronic unpredictable stress decreases the expression of VEGF, as well as its receptor, Flk-1, while ADT increases VEGF expression in the granule cell layer of the hippocampus. Different classes of chemical antidepressants, including SSRI, SNRI, and ECS, increase VEGF expression in the hippocampus, indicating that VEGF is a common downstream target of these treatments. The opposing actions of stress and ADT on VEGF suggest a possible relationship between neurogenesis and behavior. Stress has a greater effect on newborn cells associated with endothelial cells than nonvascular associated cells. In addition, VEGF is sufficient to induce neurogenesis and produce antidepressant effects in behavioral models of depression, whereas inhibition of Flk-1 blocks the induction of adult neurogenesis and the behavioral effects of ADT.

A recent postmortem study found that the expression of FGF2 and its receptors (FGFR2 and FGFR3) are reduced in the PFC and cingulate cortex of MDD patients, and social defeat stress decreases FGF2 in the hippocampus. Conversely, chronic ADT increases the expression of FGF2 in cerebral cortex and hippocampus of rodents, and FGF2 infusions are sufficient to produce an antidepressant response in behavioral models. The role of FGF2 in the proliferative actions of ADT, on both neurons and glia, is currently being investigated.

The expression of IGF-1 in the hippocampus is increased by chronic administration of two different monoamine oxidase inhibitor antidepressants. In addition to expression in brain, circulating IGF-1, derived primarily from the liver, is actively transported into the brain and is required for the induction of neurogenesis in response to exercise. Recent studies have also demonstrated that IGF-1 administration, or agents that increase IGF-1 levels, produce antidepressant-like actions in behavioral models of depression. Together, these findings suggest that peripheral production and/or the central actions of IGF-1 could be novel targets for the treatment of depression.

**Neuroprotective and neurotrophic effects of exercise**

Exercise is reported to increase the expression of neurotrophic/growth factors, including BDNF, VEGF, FGF2, and IGF-1. In addition, exercise increases neurogenesis in the adult hippocampus, an effect that is dependent on increased expression of IGF-1 and VEGF. IGF-1 has also been shown to underlie the neuroprotective effects of exercise against different types of brain insults. These positive, neuroprotective actions make exercise one of the key behavioral factors for protecting, or even reversing the damage that can be caused by environmental, physical, and psychological stressors, and even the susceptibility resulting from genetic vulnerabilities (see Figure 1).

**Glutamatergic excitotoxicity: stress, depression, and ADT**

Excess glutamatergic excitotoxicity is one of the major mechanisms underlying neuronal damage and loss in the brain, and has been implicated in the pathophysiology of a variety of disorders, including those resulting from acute insult (eg, stroke induced ischemia or trauma) and neurodegenerative disorders (eg, amyotrophic lateral sclerosis, Huntington’s chorea, epilepsy, and Alzheimer’s disease). This section discusses evidence for excess glutamate in stress related mood disorders, the cellular mechanisms that contribute to glutamate excitotoxicity, and pharmacological strategies for intervention and treatment.

**Excess glutamate in depression and stress**

Abnormal glutamate levels and function have been implicated in psychiatric illnesses, including schizophrenia, anxiety, and mood disorders. Glutamatergic abnormalities have been reported in the plasma, serum, cerebrospinal fluid (CSF), and brain tissue of individuals suffering from mood disorders. Functional in vivo measures of glutamate content in the brain using proton magnetic resonance spectroscopy (H-MRS) show elevated glutamate levels in the occipital cortex of depressed patients, although decreases have been reported in other regions.
Preclinical studies also demonstrate a role for glutamate in the actions of stress. Microdialysis studies have shown that stress increases extracellular levels of glutamate in the PFC and hippocampus, consistent with the possibility that atrophy of CA3 neurons arises in part through increased glutamate neurotransmission. This hypothesis is supported by studies demonstrating that N-methyl-D-aspartic acid (NMDA) receptor antagonists attenuate stress-induced atrophy of CA3-pyramidal neurons. Stress or glucocorticoid treatment also increases the susceptibility to other types of neuronal insults, including excitotoxins and ischemia. There are several possible mechanisms that could contribute to the overactivation of glutamate in response to stress and in depression, including a decrease or loss of mechanisms for inactivation of glutamate. Glial cells are responsible for the reuptake and inactivation of glutamate from synaptic and extrasynaptic sites. Reductions in the number or function of glia are thought to play a role in the atrophy of limbic brain regions observed in brain imaging studies, as well as decreased neuronal cell size in postmortem brains of depressed patients. Recent studies demonstrate that agents that increase glial reuptake of glutamate, such as riluzole and ceftriaxone, have antidepressant effects in rodent behavioral models and in depressed patients.

**Mechanisms of glutamate excitotoxicity**

Glutamate neurotoxicity results from excessive flux of Ca²⁺ via ionotopic receptors, including AMPA, kainate, and NMDA type receptors. Uncontrolled elevation of intracellular Ca²⁺ leads to further loss of Ca²⁺ buffering and homeostasis, and then to a cascade of events that contribute to cell damage and death. These include oxidative stress resulting in generation of reactive oxygen species (ROS) and nitric oxide, which results in necrotic cell death characterized by swelling, membrane damage, DNA degradation, and eventually inflammation and cell lysis. There are multiple sites for controlling glutamate release and activity at pre- and postsynaptic sites, as well as for buffering intracellular Ca²⁺ that protects against cell damage. These mechanisms are typically overcome only by severe conditions, such as those that would occur during stroke-induced ischemia, prolonged hypoxia, uncontrolled seizures or head trauma. As discussed above, most studies do not report a loss of neurons in postmortem tissue from depressed patients, or in animal models. However, excess glutamate is still thought to play a role in psychiatric illnesses, and this has resulted in targeting glutamatergic sites for development of therapeutic agents for mood disorders, as well as for other psychiatric, neurological, and neurodegenerative illnesses.

**Glutamate and neuroprotection: therapeutic targets**

Glutamate neurotransmission is controlled by a complex system of pre- and postsynaptic receptors, including ionotrophic and metabotropic subtypes. In addition, regulation of trophic factor signaling cascades, including extracellular signal-related kinase (ERK), Akt, and cAMP response element binding (CREB) can serve as neuroprotective targets for excitotoxicity. There is also evidence that chronic ADT regulates the phosphorylation, trafficking, and expression of glutamate receptors, providing further evidence that the actions of ADT involve this neurotransmitter system. These topics have been extensively covered by a number of recent reviews. A brief discussion of the major glutamatergic targets will be discussed here. One of the key targets for regulation of glutamate is glial reuptake, which is the primary mechanism for inactivation of glutamate neurotransmission. Agents that increase this process, notably riluzole and ceftriaxone, are reported to have antidepressant efficacy in rodent models and in clinical trials. These effects are mediated in part by increased expression of glial excitatory amino acid transporters. Riluzole also has several other interesting properties, including the ability to decrease glutamate and increase neurotrophic factor expression, making this an interesting, and potentially useful therapeutic compound. Clinical and preclinical studies are currently underway to further test the therapeutic efficacy and mechanisms underlying the actions of riluzole. Lamotrigine is another compound that acts in part by decreasing glutamate release and is used for treating mood disorders, although with limited efficacy. Blockade of the NMDA ionotropic receptor represents another primary target for neuroprotection, although this is a complex issue as glutamate is the major excitatory neurotransmitter in the brain. However, agents that block the NMDA channel, most notably memantine and ketamine, are reported to have antidepressant actions in clinical trials and rodents. The actions of memantine...
have been more modest, with greater effects when coadministered with other antidepressants. However, reports on ketamine have been extraordinary, with several studies demonstrating a rapid and sustained antidepressant response in approximately 60% of patients tested, which have all been resistant to other chemical antidepressants.139,140 A single intravenous dose of ketamine, which produces transient and mild psychotomimetic effects, results in an antidepressant response within 6 to 12 hours, and this effect is sustained for at least 7 days. These effects are dramatic compared with all other chemical antidepressants, which require weeks or months of treatment before a therapeutic response is observed. Further studies are needed to identify safer drugs that have rapid antidepressant effects similar to ketamine.

The most direct mechanism to explain the antidepressant action of ketamine is its direct inhibitory effect on NMDA receptors. In particular, the hypothesis that blockade of the extrasynaptic NR2B receptor subtype, which is activated by excess glutamate, underlies the therapeutic action of ketamine has received the most attention. This possibility is supported by a recent study demonstrating that a selective NR2B receptor inhibitor, CP-101,606, produces a rapid antidepressant response in treatment resistant MDD patients.141 Another possible mechanism to account for the rapid actions of these agents is via blockade of NMDA receptors on GABAergic inhibitory neurons, which leads to disinhibition or activation of glutamatergic transmission. The latter possibility is supported by studies in rodents demonstrating that NMDA channel blockers increase BDNF expression in limbic structures, indicating stimulation of neuronal activity,142,143 and by a recent report that the behavioral actions of ketamine are blocked by inhibition of AMPA receptor activity.144

The metabotropic glutamate receptors represent another interesting and diverse set of targets for drug development.123,136 Group I receptors, particularly mGluR1/R5 subtypes located at postsynaptic sites as well as on glia, influence both the function and release of glutamate. Drugs acting at these receptors are reported to have anxiolytic effects in rodent models. Group II receptors, mGluR2 and R3, located at presynaptic sites and on glia and regulate glutamate release, have also been targets of interest. Both agonists and antagonists of group II receptors have shown promise, with reports that mGluR2/R3 antagonists have antidepressant actions and agonists showing anxiolytic and antipsychotic effects. Most promising is a clinical report demonstrating antipsychotic efficacy of an mGluR2/3 agonist.145 Allosteric AMPA receptor potentiator (ARP) agents make up another interesting group of drugs. These agents do not directly stimulate AMPA receptors, but slow the inactivation or desensitization of the receptors. The idea of using drugs that enhance AMPA receptor function would appear to be counterintuitive given the possibility of an overactive glutamate system. However, preclinical studies of these agents, which were first developed for enhancing cognition, demonstrate positive antidepressant-like effects in rodent models of depression.123,146

### Programmed cell death (apoptosis) in stress and depression

Programmed cell death is a critical mechanism for regulation of the appropriate complement of neurons during development, but apoptotic signaling pathways are also regulated in the adult brain and influence the number and function of mature cells. Apoptosis is a highly regulated signaling process, which includes the Bcl-2 family of proteins, cytochrome C, a cytosolic adaptor protein, and caspase activation, which results in energy-dependent death.135,147 The Bcl-2 family includes antiapoptotic factors (ie, Bcl-2 and Bcl-xl) that antagonize proapoptotic factors (eg, Bax and Bak). Upon activation of apoptotic pathways, Bax and Bak insert into the mitochondrial membrane and promote the release of cytochrome C, which in turn binds to the apoptotic activator factor (Apaf1), leading to activation of caspases 9 and 3.

### Regulation of apoptosis by depression, stress, and ADT

Analysis of postmortem tissue and rodent models has provided some evidence for apoptotic cell death and/or signaling in depression and stress.135 There is a postmortem report of low levels of apoptosis in the temporal cortex and hippocampus of depressed patients.148 Rodent studies demonstrate that social stress increases the number of apoptotic cells in the hippocampus and temporal cortex,149 and chronic unpredictable stress increases the number of caspase 3 positive neurons in the cerebral cortex.150 Maternal separation of rats is also reported to increase cell death in the dentate gyrus of hippocampus.151
Genetic association studies have also provided evidence for a link between apoptosis signaling and depression. Polymorphisms of the adaptor protein Apaf1 were found to be associated with major depression. These polymorphisms increase the activity of caspase 9 and would thereby increase the vulnerability of neurons to apoptotic cell death. There are also several studies that have examined levels of apoptotic signaling proteins in models of stress and ADT. Chronic unpredictable stress is reported to decrease levels of the antiapoptotic factors Bcl-2 and Bcl-xl, but does not influence levels of Bax. Administration of a high dose of adrenal-glucocorticoids reduces Bcl-2 levels, and this effect corresponds with increased sensitivity to excitotoxic damage. Conversely, chronic ADT increases the expression of Bcl-2 and/or Bcl-xl in limbic brain regions. Chronic administration of lithium or valproate also increases Bcl-2 in the hippocampus and PFC. The antiapoptotic actions of lithium and valproate have also been demonstrated in studies of cultured cells. Antidepressants also influence other signaling cascades that indirectly influence apoptotic processes. Most notable are the effects of stress and ADT on neurotrophic factors and related signaling cascades, including ERK and Akt, which increase cell survival in part via inhibition of apoptotic, and induction of antiapoptotic factors such as Bcl-2. Finally, it is also notable that certain members of the Bcl-2 family have also been implicated in other cellular functions, including neurotransmission, which could be involved in the actions of stress and ADT. Mitochondria play a primary role in the storage, processing, and release of proteins involved in apoptosis, and recent studies demonstrate a role for other aspects of mitochondrial function in the pathophysiology and treatment of mood disorders.

**Inflammation/immune responses**

Inflammation and immune responses are major factors contributing to the etiology and pathophysiology of many medical illnesses, including depression and other psychiatric disorders. Inflammation can be caused by other medical conditions, including infection, stroke, trauma, and abnormal or autoimmune responses. However, it is also now clear that psychological stress, such as social stress, can activate the innate immune system, elevating cytokine production, and thereby stimulate inflammatory processes. Inflammatory and immune processes can lead to multiple actions that have acute protective actions, but that also can have damaging effects on cells and tissue. This includes many of the same actions implicated in the responses to stress and depression, including activation of the HPA axis, alterations of neurotransmitter systems, decreased neurotrophic factor expression, and increased oxidative stress. Depending on the severity and length of the inflammatory response, these effects can result in significant actions on neuronal and glial function and cell survival or death.

There are several proinflammatory cytokines of interest, including IL-1, IL-6, and tumor necrosis factor (TNF)α, that have been implicated in the pathophysiology and treatment of depression. Also of interest are studies of interferon-α, used for the treatment of hepatitis or cancer, which results in depressive-like symptoms in a large number of patients. Here we discuss a few of the most interesting targets for treatment of depression; for a more thorough review see ref 167.

**TNFα and depression**

One of the most consistently altered proinflammatory cytokines in depressed subjects is TNFα. An inverse correlation between levels of TNFα and treatment response has been reported. TNFα immunotherapy also causes depression, indicating that this cytokine may contribute to the etiology of mood disorders and is not simply a marker for depression (for reviews see refs 168,170). Moreover, a recent large clinical trial using an antibody neutralization approach demonstrated significant antidepressant effects of TNFα reduction. This finding is supported by preclinical studies demonstrating that TNFα infusions produce a pro depressive effect, and that TNFα receptor null mutant mice have an antidepressant phenotype in the forced swim and sucrose consumption tests. Taken together, the preclinical and clinical studies provide strong support for TNFα receptors, particularly TNFR2, as targets for the treatment of mood disorders.

**IL-1β, stress, and depression**

There is also strong evidence that the proinflammatory cytokine IL-1β plays a key role in the pathophysiology of
stress and depression, and that the IL-1β signaling is a relevant target for drug development. These findings include: i) clinical studies reporting an increase in serum levels IL-1β in MDD; ii) reports that IL-1β produces stress like effects, including activation of the HPA axis, regulation of monoamines, and behavioral responses in rodent models; iii) evidence that IL-1β contributes to conditioned fear and depressive like behavior, and produces anhedonia and disrupts incentive motivation in rodent models; iv) preclinical reports that IL-1β decreases hippocampal neurogenesis and underlies the decrease observed in response to stress; v) our report that CUS-induced anhedonia and decreased neurogenesis produced by is blocked by pharmacological inhibition or null mutation of IL-1β receptors. Studies are currently underway to determine if blockade of peripheral, as well as central IL-1β signaling is sufficient to block the effects of stress and produce antidepressant actions.

**Interferon and IDO**

Recent studies demonstrate that one of the key factors contributing to the depressive actions of inflammation and activation of the innate immune system is the induction of a tryptophan degradative enzyme, indoleamine 2,3-dioxygenase (IDO). Chronic inflammation and infection can lead to sustained induction of interferon, which is then responsible for the increased levels of IDO. The induction of IDO then results in diversion of tryptophan from the synthesis of serotonin to kyneurenic acid, which can be further converted to toxic metabolites, most notably quinolinic acid. Evidence for IDO in depression is supported by studies demonstrating that decreased levels of tryptophan and increased kynurenin is associated with inflammation and depression. Increased IDO has also been positively correlated with depression, although a direct causal relationship has not been demonstrated.

A recent study has now provided direct evidence that induction of IDO underlies the depressive behaviors caused by inflammation/activated immunologic conditions. This work was conducted using a bacterial immune activation model, Bacille Calmette-Guerin (BCM), which induces a long-lasting induction of interferon and results in depressive behaviors in animal models. The results demonstrate that BCM-mediated immobility in the forced swim test is reversed by an IDO inhibitor, 1-methyltryptophan, and in mice that are deficient in IDO. In addition, BCM also increases the expression of a downstream enzyme, 3-hydroxyanthranilic acid oxygenase (3-HAO) that is involved in the synthesis of quinolinic acid. These studies indicate that an IDO inhibitor, and possibly an inhibitor of 3-HAO, could have efficacy for the treatment of depression and related mood disorders.

**Summary and future directions**

Significant advances have been made in characterizing the neuronal and glial damage, or structural alterations, at the cellular and anatomical levels in stress-related mood disorders and other psychiatric illnesses, and in elucidating the molecular signaling pathways and mechanisms that underlie these changes. However, this work is still at a relatively early stage, and a more complete characterization of these complex alterations and signaling mechanisms will require extensive resources and time. Moreover, identification of genetic polymorphisms that impact these pathways and systems and that influence susceptibility or resilience to illness is a major area of research that will continue to develop and unfold. When combined with studies of environmental risk factors and lifetime history of stress, this work will define and describe the mechanisms underlying individual variations of illness.

Together, the results of this work can be used to formulate a comprehensive approach for the prevention and treatment of psychiatric illnesses. Changes in lifestyle and behavior can reduce stress and exposure to environmental factors that influence cellular risk and damage and prevent illness. These approaches, as well as behavioral interventions that enhance the activity and function of specific neural circuits, and thereby provide protection, can also be used once a person has become ill. Development of therapeutic agents that target neuroprotective mechanisms, combined with genetic information will ultimately provide tailored approaches for highly specific and efficacious treatments for depression and other illnesses.

Acknowledgements: This work is supported by USPHS grants MH45481 and 2 P01 MH25642 and by the Connecticut Mental Health Center. We would also like to thank Mr Xiaowe Su for assistance with literature research, and Drs G. Aghajanian and R-J. Li for providing images of PFC dendrites in Figure 2.
| References |
|------------|
| 1. Duman R, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127. |
| 2. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894-902. |
| 3. McEwen B. Sex, stress and the hippocampus: allostatic load and the aging process. Neurobiol Aging. 2002;23:921-939. |
| 4. Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007;10:1110-1115. |
| 5. Campbell S, MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psych. 2006;19:25-33. |
| 6. Drevets W. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;48:813-829. |
| 7. Manji H, Quiraz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53:707-742. |
| 8. Tanis K, Newton SS, Duman RS. Targeting neurotrophic growth factor expression and signaling for antidepressant drug development. CNS Neurol Disord. 2007;6:151-160. |
| 9. Bremner JD, Vermetten E, Mazure CM. Development and preliminary psychometric properties of an instrument for the measurement of childhood trauma: the Early Trauma Inventory. Depression Anxiety. 2000;12:1-12. |
| 10. Mervala E, Fohr J, Kononen M, et al. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med. 2000;30:117-125. |
| 11. Sheline Y, Wang P, Gado MH, Cernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996;93:3908-3913. |
| 12. Sheline Y, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999;19:5034-5043. |
| 13. Campbell S, Marriott M, Nahinis C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry. 2004;161:598-607. |
| 14. Videbech P, Ravnikilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957-1966. |
| 15. Sheline Y, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-1518. |
| 16. Bremner JD, Randall, P, Scott TM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry. 1995;152:973-981. |
| 17. Gurvits T, Shenton ME, Hikama H, et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related post traumatic stress disorder. Biol Psychiatry. 1996;40:1091-1099. |
| 18. Hecker S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus. 2001;11:529-528. |
23. Cotter D, Pariente CM, Everall IP. Giall cell abnormalities in major psychiatric disorders: the evidence and implications. Br Res Bull. 2001;51:555-559.

24. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085-1098.

25. Ongh D, Drevets WC, Price JL. Giall reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A. 1998;95:13290-13295.

26. Si X, Miguel-Hidalgo JJ, O'Dwyer G, Stockmeier CA, Rajkowska G. Age-dependent reductions in the level of gial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacol. 2004;29:2088-2096.

27. Huard M, Drevets WC, Price JL. Giall reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry. 2004;55:563-569.

28. Uruno N, Vostrikov VM, Orlovskaya DO, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study for the Stanley Neuropathology Consortium. Schzophr Res. 2004;67:269-275.

29. McEwen B. Stress and hippocampal plasticity. Curr Opin Neurobiol. 1999;9:205-216.

30. Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol. 1992;222:157-162.

31. Radley J, Sidd HM, Hao J, et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neurosci. 2004;125:1-6.

32. Magarinos AM, McEwen BS, Flugge G, Fuchs E. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci. 1996;16:3353-3340.

33. Wellman C. Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J Neuroendocrinol. 2001;49:245-253.

34. Radley J, Rocher AB, Miller M, et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex. 2006;16:313-320.

35. Gangpart S. Mammalian neuromodulation. Science. 2000;287:1433-1438.

36. Gould E, Tanapat P. Stress and hippocampal neurogenesis. J Neurosci. 1999;46:1472-1479.

37. Warner-Schmidt J, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus. 2006;16:239-249.

38. Banas M, Valentine GW, Li XY, Gourley S, Taylor J, Duman RS. Chronic stress decreases cell proliferation in adult cerebral cortex of rat: reversal by antidepressant treatment. Biol Psychiatry. 2007;62:496-504.

39. Alonzo G. Prolonged corticosterone treatment of adult rats inhibits the proliferation of oligodendrocyte progenitors present throughout white and gray matter regions of the brain. Glia. 2000;31:219-231.

40. Czeh B, Simon M, Schmitting B, Hiemke C, Fuchs E. Astroglial plasticity in the hippocampus is effected by chronic psychosocial stress and comitant fluoxetine treatment. Neuropsychopharmacol. 2006;31:1616-1626.

41. Maiborg J, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J Neurosci. 2000;20:9104-9110.

42. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neuorgenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809.

43. Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine treatment increases cell proliferation in rat hippocampus and frontal cortex. J Biol Psych. 2004;56:570-580.

44. Madsen T, Newton SS, Eaton ME, Russell DS, Duman RS. Chronic electroconvulsive seizure up-regulates b-catenin expression in rat hippocampus: role in adult neurogenesis. Biol Psychiatry. 2003;54:1006-1014.

45. Airan R, Meltzer LA, Roy M, Gong Y, Chen H, Deisseroth K. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science. 2007;317:757-758.

46. Jiang X, Xu K, Hoberman J, Tian F, et al. BDNF variation and mood disorders: a novel functional polymorphism polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacol. 2005;30:1353-1361.

47. Bessa J, Ferreira D, Melo I, et al. Hippocampal neurogenesis is induced by antidepressant drugs: an epiphenomenon in their mood-improving actions. Mol Psych. 2009;14:739.

48. David D, Klemenhagen KC, Hocik KA, et al. Efficacy of the MCH1 antagonist N-[3-(1-[4-(3,4-difluorophenoxy)phenyl]-3-piperidyl)]-4methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J Pharmac Exp Ther. 2007;321:237-248.

49. Banas M, Duman RS. Giall loss in prefrontal cortex is sufficient to induce depressive-like behaviors in rodent models. Biol Psychiatry. 2008;64:863-870.

50. Drevets WC, Miller MM, Goldwater DS, et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci. 2006;26:7870-7874.

51. Lupien S, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci. 2009;10:434-445.

52. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.

53. Risch N, herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, risk of depression: a meta-analysis. JAMA. 2009;301:2462-2471.

54. Feder A, Nestler EJ, Charney DS. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci. 2009;10:446-457.

55. McEwen B. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol. 2008;583:174-185.

56. McAllister A. Spatially restricted actions of BDNF. Neuron. 2002;36:549-550.

57. Smith MA, Makino S, Kvetnansky R, Post RM. Stress alters the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995a;15:1768-1777.

58. Xu H, Chen Z, He J, Haimanot S, Li X, Dyck L, Li XM. Synergistic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus. 2006;16:551-559.

59. Chen B, Dowlatshahi D, MacQueen GM, Wang J-F, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260-265.

60. Dwivedi Y, Rizavi HS, Conley RR, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatriy. 2003b;60:804-815.

61. Karege F, Bondolfi G, Gervasio N, Schwind M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry. 2005;57:1068-1072.

62. Metsis M, Timmusk T, Arenas E, Persson H. Differential usage of multiple BDNF promoters in the rat brain following neuronal activation. Proc Natl Acad Sci U S A. 1993;90:3892.

63. Barrientos R, Sprunger DB, Campeau S, et al. Brain-derived neurotrophic factor mRNA downregulation induced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuron. 2003;12:847-853.

64. Tsankova N, Berton O, Renthal W, Kumar A, Neve R, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9:465-466.
65. Egan M, Kojima M, Callicott JH, et al. The BDNF val66met polymor-
phism affects activity-dependent secretion of BDNF and human
memory. J. Neurosci. 2003;23:112-27.
66. Frodl T, Schule C, Schmitt G, et al Association of the brain-derived neu-
rotrophic factor Val66Met polymorphism with reduced hippocampal vol-
umes in major depression. Arch Gen Psychiatry. 2007;64:410-416.
67. Hariri A, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic
factor val66 met polymorphism affects human memory-related hippoc-
campal activity and predicts memory performance. J Neurosci. 2003;23:66094.
68. Matsuo K, Wals-Bass C, Nery FG, et al. Neuronal correlates of brain-
derived neurotrophic factor Val66Met polymorphism and morphometric
abnormalities in bipolar disorder. Neuropsychopharmacol. 2009;34:1904-1913.
69. Gatt J, Nemeroff CB, Dobson-Stone C, et al. Interactions between
BDNF val66 Met polymorphism and early life stress predict brain and
arousal pathways to syndromal depression and anxiety. Mol. Psych. 2009;14:681-695.
70. Kaufman J, Yang BZ, Douglas-Palumberi H, et al. Brain-derived neu-
rotrophic factor-5-HTTLP gene interactions and environmental modifi-
cations of depression in children. Biol Psychiatry. 2006;59:673-680.
71. Kim J, Steward R, Kim SW, et al. Interactions between life stressors and
sustainability genes (5-HTTLP and BDNF) on depression in Korean elders. Biol Psych. 2007;62:423-428.
72. Lee Y, Duman RS, Marek GJ. The mGlur2 receptor agonist LY354740
suppresses immobilization stress-induced increase in rat prefrontal cortical
BDNF mRNA expression. Neurosci Lett. 2006;398:329-332.
73. Liu R-J, Aghajanian GK. Stress blunts serotonin- and hypocretin-
evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical
dendritic atrophy. Proc Natl Acad Sci U S A. 2008;105:339-346.
74. Chen H, Pandey GN, Dwivedi Y. Hippocampal cell proliferation regula-
tion by repeated stress and antidepressants. Neuropeptides. 2006;17:863-867.
75. Monteggia L, Barrot M, Powell CM, et al. Essential role of brain-
derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A. 2004;101:10827-10832.
76. Monteggia L, Luikart B, Barrot M, et al. Brain-derived neurotrophic factor
cellular knockouts show gender differences in depression-related
behaviors. Biol Psych. 2007;61:187-197.
77. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the trkB neu-
rotrophin receptor is induced by antidepressant drugs and is required for
 antidepressant-induced behavioral effects. J Neurosci. 2003;23:349-357.
78. Dijkhuizen L, Schlesinger L, Kodama M, Russell DS, Duman RS. A role for
MAPK signaling in behavioral models of depression and antidepressant
treatment. Biol Psych. 2007;61:661-670.
79. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the
dentate gyrus. Proc Natl Acad Sci U S A. 1997;94:131-137.
80. Ferrara N, Gerber HP, LeCouuter J. The biology of VEGF and its recep-
tors. Nat Med. 2003;9:669-676.
81. Heine V, Zareno J, Maslam S, Joels M, Lucassen PJ. Chronic stress in the
dentate gyrus reduces cell proliferation near the vasculature and
VEGF and Flk-1 protein expression. Eur J Neurosci. 2005;21:1304-1314.
82. Palmer T, Willhoite AR, Gage FH. Vascular niche for adult hippocam-
pal neurogenesis. J Comp Neurol. 2000;425:479-494.
83. Warner-Schmidt J, Duman RS. VEGF is an essential mediator of neuro-
genic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A. 2007;104:4647-4652.
84. Evans S, Choudhry PV, Neal CR, et al. Dysregulation of the fibroblast
growth factor system in major depression. Proc Natl Acad Sci U S A. 2004;101:15506-15511.
85. Turner C, Gula EL, Taylor LP, Watson SJ, Akil H. Antidepressant-like
effects of intracerebroventricular FG22 in rats. Brain Res. 2008;1224:206-210.
86. Mallei A, Shi B, Mocchetti I. Antidepressant treatments induce the
expression of basic fibroblast growth factor in cortical and hippocampal
neurons. Mol Pharmacol. 2002;61:1017-1024.
87. Maragolini F, Fumagalli F, Gennarelli M, Racagni G, Riva MA.
Fluoxetine and olanzapine have synergistic effects in the modulation of
BDNF and trkB receptors: roles in plasticity, neurodegenerative
and neuroprotection. Biochem Soc Trans. 2007;35(5 Pt 2):424-427.
88. Han B, Holtzman DM. BDNF protects the neonatal brain from hypoxic-
ischemic injury in vivo via the ERK pathway. J Neurosci. 2000;20:5775-5781.
89. Miyata K, Miyata N, Omori H, et al. Involvement of the brain-derived
neurotrophic factor/TrkB pathway in neuroprotective effect of
cyclosporin A in forebrain. Neurosci. 2001;105:571-578.
90. Sun X, Zhou H, Luo X, Li S, Yu D, Hua J, Mu D, Mao M. Neuroprotection
of brain-derived neurotropic factor against hypoxic injury in vitro requires
activation of extracellular signal-regulated kinase and phosphatidylinosi-

tol 3-kinase. Intl J Dev Neurosci. 2008;26:363-370.
91. Walton M, Walhout B, Connor P, et al. Neuronal death and survival in two
models of hypoxic-ischemic brain damage. Brain Res Rev. 1999;29:137-168.
92. Arancio O, Chao MV. Neurotrophins, synaptic plasticity and dementia. Cur
Curr Opin Neurobiol. 2007;17:325-330.
93. Henning A, O'Callaghan RM, Kelly AM. Neurotrophins and their
receptors: roles in plasticity, neurodegeneration and neuroprotection.
Biochem Soc Trans. 2007;35(5 Pt 2):424-427.
94. Pencea V, Bingaman, KD, Wiegand SJ, Luskin MB. Infusion of brain-
derived neurotrophic factor into the lateral ventricle of the adult rat leads
to new neurons in the parenchyma of the striatum, septum, thalamus, and
hypothalamus. J Neurosci. 2001;21:6706-6717.
95. Scharfman H, MacLusky NJ. Similarities between actions of estrogen
and BDNF in the hippocampus: coincidence or due? Trends Neurosci. 2005;28:79-85.
96. Sairanen M, Lucas G, Ernors R, Castren M, Casren E. Brain-derived
neurotrophic factor and antidepressant drugs have different but coordi-
nated effects on neuronal turnover, proliferation, and survival, and in the adult
dentate gyrus. J Neurosci. 2005;25:1089-1094.
97. Li Y, Luikart BW, Birnbaum S, et al. TrkB regulates hippocampal neu-
rogenesis and governs sensitivity to antidepressive treatment. Neuro-
neurulation. 2008:39:399-412.
98. Hoshaw B, Malberg JE, Lucki I. Central administration of IGF-I and
BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005;1037:204-208.
99. Shirayama Y, Chen, A-C-H, Nakagawa S, Russell RS, Duman RS. Brain
derived neurotrophic factor produces antidepressant effects in behavioral
models of depression. J Neurosci. 2002;22:3251-3261.
100. Siuciak JA, Lewis DR, Wiegand, SJ, Lindsay, R. Antidepressant-like
effect of brain derived neurotrophic factor (BDNF). Pharmacol Biochem Behav. 1997;56:131-137.
101. Ferrara N, Gerber HP, LeCouuter J. The biology of VEGF and its recep-
tors. Nat Med. 2003;9:669-676.
102. Heine V, Zareno J, Maslam S, Joels M, Lucassen PJ. Chronic stress in the
dentate gyrus reduces cell proliferation near the vasculature and
VEGF and Flk-1 protein expression. Eur J Neurosci. 2005;21:1304-1314.
103. Palmer T, Willhoite AR, Gage FH. Vascular niche for adult hippocam-
pal neurogenesis. J Comp Neurol. 2000;425:479-494.
104. Warner-Schmidt J, Duman RS. VEGF is an essential mediator of neuro-
genic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A. 2007;104:4647-4652.
Neurobiol lar suicide (apoptosis) in depression and the antidepressant response?

mal model of depression: Reversal of stress-induced cellular, metabolic and lar mechanisms.

131. Malberg J, Platt B, Rizzo SJS, et al. Increasing the levels of insulin-like growth factor-1 by an IGF binding inhibitor produces anxiolytic and anti-depressant-like effects. Neuropsychopharmacol. 2007;32:2360-2368.

132. Fabel K, Fabel K, Tam B, et al. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci. 2003;18:2803-2812.

133. Gomez-Pinilla F, Dao L, Zanotelli M. Physical exercise induces FGF-2 and its mRNA in the hippocampus. Brain Res. 1997;764:1-8.

134. Bunjes J, Newton SS, Bennett AH, et al. Antidepressant actions of the exercise-regulated gene VGF. Nat Med. 2007;13:1476-1482.

135. Fusetti D, Ubeda B, Nissi E, et al. Exercise protects against brain insults due to abnormal etiology and anatomy. J Neurosci. 2001;21:5678-5684.

136._yellow text

137. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: A con-Valentine G, Sanacora G. Targeting glial physiology and glutamate roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30:464-472.

138. Dong X, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30:379-387.

139. Kalia L, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7:742-755.

140. Amiel J, Mathew SJ. Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007;9:278-283.

141. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the gluta-matric system to develop novel, improved therapies for mood disor-der. Nat Rev Drug Discov. 2008;7:426-437.

142. Dodhia M, Wood KH, Meador-Woodruff J. Role of glutamate in schizo-phrenia: integrating excitatory avenues of research. Exp Rev Neurother. 2008;8:1399-1406.

143. Sanacora G, Guerguevieu R, Eperson CN, et al. Subtype-specific alter-ations of y-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004b;6:1:705-713.

144. Lowry M, Wittenberg L, Yamamoto B. Effect of acute stress on hip-pocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem. 1995;65:268-274.

145. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem. 1993;60:1650-1657.

146. Sapolsky R. Glucocorticoids and atrophy of the hippocampus. Science. 1996;273:749-750.

147. Sapolsky R. The possibility of neurotubularity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry. 2000;48:755-765.

148. McEwen B. Estrogens effects on the brain: multiple sites and molecu-lar mechanisms. J Appl Physiol. 2001;91:2785-2801.

149. Roy M, Sapolsky RM. The exacerbation of hippocampal excitotoxicity by glucocorticoids is not mediated by apoptosis. Neuroendoctrinol. 2003;77:24-31.

150. Banasr M, Chowdhury GM, Newton SS, et al. Glial pathology in an ani-mal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate modulating drug riluzole. Mol Psychol. In press.

151. Valentine G, Sanacora G. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol. 2009;78:431-439.

152. Kittenger C, Duman RS. Stress, depression, and neuroplasticity: A con-vergence of mechanisms. Neuropsychopharmacol. 2008;33:88-109.

153. McKernan D, Dinan TG, Cryan JF. “Killing the Blues:” A role for cellu-lar suicide (apoptosis) in depression and the antidepressant response? Prog Neurobiol. 2009;88:246-263.

154. Conn P, Jones CK. Promise of mGluR2/3 activators in psychiatry. Neuropsychopharmacol. 2009;34:248-249.

155. Lipton S. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8:621-632.

156. Mineur Y, Somenzi O, Picciotto MR. Cytosine, a partial agonist of high affinity nicotinic acetylcholine receptors, has antidepressant-like proper-ties in male C57BL/6J mice. Neuropharmacol. 2007;52:1256-1262.

157. Berman R, Cappiello A, Anand A, et al. Antidepressant effects of ket-amine in depressed patients. Biol Psychiatry. 2000;47:351-354.

158. Zarate C, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psych. 2006;59:1006-1020.

159. Patki S, Shrivastava DK, Jaiswal A, et al. Antidepressant effects of ket-amine in drug-resistant depression (TRD). Paper presented at: APA. 2007.

160. Castren E, da Penha Berzaghi M, Lindholm D, Thoenen H. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp Neurol. 1993;122:244-252.

161. Takahashi M, Kikuta A, Futamura T, et al. Sustained brain-derived neu-rotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phenylalanine: comparison with adult treatment. J Neurochem. 2006;99:770-780.

162. Maeng S, Zarate CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2007;63:349-352.

163. Patil S, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102-1107.

164. Su X, Li X-Y, Banasr M, Koo JW, Shahid M, Henry B, Duman RS. Chronic treatment with AMPA receptor potentiator Org 16576 increases neuronal cell proliferation and survival in adult rodent hippocampus. Psychopharmacol. 2009. In press.

165. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647-656.

166. Lucassen P, Muller MB, Holsboer F, et al. Hippocampal apoptosis in major depression is a minor event and absent from sub-areas at risk for glucocorticoid overexpression. Am J Pathology. 2001;158:453-468.

167. Lucassen P, Vollmann-Hon-dorf GK, Giesebregt M, Czeh B, De Kloet ER, Fuchs E. Chronic psychosocial stress differentially affects apoptosis in hip-pocampal subregions and cortex of the adult tree shrew. Eur J Neurosci. 2001;14:161-166.

168. Bachs A, Mallesi A, Cruz MM, Wellstein A, Mocchetti I. Chronic anti-depressant treatments increase basic fibroblast growth factor and fibrob-last growth factor-binding protein in neurons. Neuropharmacol. 2008;55:1114-1120.

169. Lee J, Duan W, Mattson MP. Evidence that brain-derived neurotroph-ic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurosci. 2002;22:1367-1375.

170. Harlan J, Chen Y, Gubbins E, Mueller R, et al. Variants in Apaf-1 seg-reating with major depression promote apoptosis function. Mol Psych. 2006;11:76-85.

171. Koster T, Galloway D, Duman RS, D’Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the Bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacol. 2008;33:1545-1558.

172. Xu B, Goulding EH, Zang K, et al. Brain-derived neurotrophin factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 2003;6:736-742.
Neuroprotection and depression - Duman

157. Chen R, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem. 1999;274:6039-6042.

158. Bielecka A, Obuchowicz E. Antiapoptotic action of lithium and valproate. Pharmacol Rep. 2008;60:771-782.

159. Chuang D. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci. 2005;1053:195-204.

160. Chuang D, Manji HK. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psych. 2007;62:4-6.

161. Coyle J, Duman, RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron. 2003;38:157-160.

162. Jonas E, Holt D, Hickman JA, et al. Modulation of synaptic transmission by the BCL-2 family protein BCL-xl. J Neurosci. 2003;23:8423-8431.

163. Bachman R, Wang Y, Yuan P, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol. 2009;12:805-822.

164. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psych Neurosci. 2009;34:4-20.

165. Grippo A, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical models. Stress. 2009;12:1-12.

166. Khairova R, machado-Vieira R, Du J, Manji HK. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2009;12:561-578.

167. Miller A, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psych. 2009;65:732-741.

168. Anisman H, Merali Z. Cytokines, stress and depressive illness. Brain Behav Immun. 2002;16:513-524.

169. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebye M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;40:171-176.

170. Anisman H, Hayley S, Turin N, Merali Z. Cytokines as a stressor: implications for depressive illness. Int J Neuropsychopharmacol. 2002;5:357-373.

171. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriatic: double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29-35.

172. Reynolds J, Ignatowski TA, Sud R, Spengler RN. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neurosc. 2005;133:519-531.

173. Simen B, Duman OH, Simen AA, Duman RS. TNF alpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry. 2006;59:775-785.

174. Koo J, Duman RS. IL-1B is an essential mediator of the anti-neurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A. 2008;105:751-756.

175. Koo J, Duman RS. IL-1 receptor null mice show decreased anxiety and enhanced fear memory. Neurosc Lett. 2009. In press.

176. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacol. 2000;22:370-379.

177. Maes M, Meltzer HY, Booms R, Bergmans R, Vandoolaege E, Ranjan R. Increased plasma concentrations of interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Dis. 1995;34:301-309.

178. Mikova Q, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol. 2001;11:203-208.

179. Sluzewska A, Rybakowski JK, Laclak M, Mackiewicz A, Sobieska M, Witkowizc K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals NY Acad Sci. 1995;762:474-476.

180. Tuglu C, Kara SH, Calkyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacol (Berl). 2003;170:429-433.

181. Connor T, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998;62:583-606.

182. Maier S, Watkins LR. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res. 1995;695:279-282.

183. Merali Z, Brennan K, Brau P, Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1beta: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacol. 2003;165:413-418.

184. Koo J, Duman RS. IL-1B is an essential mediator of the anti-neurogenic and anhedonic effects of stress. Soc Neurosci Abst. 2008;105:751-756.

185. O’Connor J, Lawson MA, Andre C, et al. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol. 2009;182:3202-3212.

186. O’Connor J, Lawson MA, Andre C, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci. 2009;29:4200-4209.